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1. Introduction
A chronic autoimmune destruction of the pancreatic beta cells results in decreasing endoge‐
nous insulin secretion and the clinical manifestation of type 1 diabetes mellitus (T1DM). The
clinical onset of the disease is often acute in children and adolescents and diabetic ketoaci‐
dosis (DKA) is present in 20-74% of the patients [1-7]. DKA is a serious condition that re‐
quiring immediate intervention. Even with appropriate intervention, DKA is associated
with significant morbidity and possible mortality in diabetic patients in the pediatric age
group [8]. Young age and female sex have been associated with an increased frequency of
DKA [3,9]. The triad of uncontrolled hyperglycemia, metabolic acidosis and increased total
body ketone concentration characterizes DKA [10]. In addition to possible acute complica‐
tions, it may also influence the later outcome of diabetes [11].
2. Epidemiology
Worldwide, an estimated 65 000 children under 15 years old develop T1DM each year, and
the global incidence in children continues to increase at a rate of 3% a year [12,13]. The cur‐
rent incidence in the UK is around 26/100 000 per year [14]. Patterson et al. were aimed to
establish 15-year incidence trends for childhood T1DM in European centres with EURO‐
DIAB study. 29 311 new cases of T1DM were diagnosed in children before their 15th birth‐
day during a 15-year period between 1989-2003. The overall annual increase was 3.9% and
the increases in the age groups 0-4 years, 5-9 years, and 10-14 years were found to be 5.4%,
4.3%, and 2.9% respectively. If present trends continue, prevalent cases younger than 15
years will rise by 70% in 2020 [15].
The incidence of DKA was found to be 5-8% in large community-based studies [16]. Ap‐
proximately 115 000 patients admitted to the hospital because of DKA in one year in USA
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[17]. In a Turkish study conducted among the patients with diabetic adults who admitted to
the hospital, the ratio of T1DM was found to be 6.6% and DKA was 38% of the group [18].
There is wide geographic variation in the frequency of DKA at onset of diabetes. The ratio
inversely correlates with the regional incidence of T1DM. Frequencies range from 15 to 70%
in Europe, Australia, and North America [11,19-25]. The most occurrence ages of DKA are
between the 18-44 years (56%), than 45-65 years (24%) continues with only 18% of patients
<20 years of age. Two-thirds of DKA patients are considered to have T1DM and 34% to have
type 2 diabetes. DKA is the most common cause of death in children and adolescents with
T1DM. Half of all deaths in diabetic patients younger than 24 years of age are caused from
DKA [26,27]. In adult subjects with DKA, the overall mortality is usually given <1% (13),
however mortality rates may increase over 5% in the elders and in patients with concomi‐
tant life-threatening illnesses [28,29].
3. Pathogenesis
There are some factors as a reason of acute metabolic complications in diabetic patiens.
These factors are insulin deficiency as the initial primary event in progressive beta-cell fail‐
ure, its failure in a patient with established disease or its ineffectiveness when insulin action
is antagonized by physiological stress such as sepsis and in the context of counterregulatory
hormone (catecholamines, cortisol, glucagon, and growth hormone) excess. These hormonal
changes increase glucose production from glycogenolysis and gluconeogenesis and impair
glucose utilization by peripheral tissues, resulting in hyperglycemia, osmotic diuresis, elec‐
trolyte loss, dehydration, decreased glomerular filtration (further compounding hyperglyce‐
mia) and hyperosmolarity. [26, 30-35].
The combination of insulin deficiency and increased counterregulatory hormones in DKA
also leads to the release of free fatty acids into the circulation from adipose tissue (lipolysis).
This is augmented by transient insulin resistance due to the hormone imbalance itself as
well as the elevated free fatty acid concentrations [8,10,26,28-39]. Uncontrolled hepatic fatty
acid oxidation in the liver to ketone bodies (beta-hydroxybutyrate and acetoacetate) results
ketonemia and metabolic acidosis [40]. The pathogenesis causing to hyperglycemia and ke‐
toacidosis are schematized in Figure 1 [30].
A number of clinical studies showed that the hyperglycemia in patients with hyperglycemic cri‐
ses is associated with a severe inflammatory state characterized by an elevation of proinflam‐
matory cytokines tumor necrosis factor alpha (TNF-α) and interleukin-6, and -8 (IL-6,8), C-
reactive protein, reactive oxygen species, and lipid peroxidation, as well as cardiovascular risk
factors, plasminogen activator inhibitor-1 and free fatty acids in the absence of obvious infec‐
tion or cardiovascular pathology. Insulin therapy and hydration recover these parameters to
near-normal values within 24 hours [41]. Recent studies focused on the role of interleukin-1 be‐
ta (IL-1ß), interleukin-12 (IL-12) and interferon-gamma (IFN-γ). As demonstrated in vitro, these
cytokines can directly influence beta cell function and viability [42]. Karavanaki et al. studied
plasma levels of cytokines IL-1β, interleukin-2 (IL-2), IL-6, IL-8, and interleukin-10 (IL-10), TNF-
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α and also white blood cell count (WBC), high sensitivity C-reactive protein (hs-CRP), growth
hormone (GH) and cortisol in 38 newly diagnosed T1DM children with DKA (mean age
7.68±3.07 years), prior to, during and 120 hours after DKA management, with the aim to moni‐
tor their levels at different time-points and in different degrees of DKA severity. Prior to DKA
management the levels of IL- 6, IL-8, IL-10,WBC and cortisol were elevated, but all parameters
were reduced within 120 hours after DKA management [43].
Figure 1. The pathogenesis causing to hyperglycemia and ketoacidosis in DKA (Data adapted from reference [17])
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Recent studies have reported that an upregulated production of and interleukin-18 (IL-18)
could be an important pathogenic event in the dysregulated production of IFN-γ and other
type 1 cytokines thought to predispose T1DM [44-46] and the potential role of IL-18 in the
pathophysiology of the chronic complications of diabetes mellitus [7-11]. But the potential
role of IL-18 in the acute complications of diabetes mellitus such as DKA is controversial.
Dong et al. compared serum IL-18 levels and other cytokines (IL-12 and IFN-γ) in newly di‐
agnosed T1DM with DKA, T1DM without DKA and age/sex-matched healthy controls. Se‐
rum IL-18 levels were significantly higher in patients than those in healthy controls. Serum
IL-12 and IFN-γ levels were not different between patients and controls. But there was a
positive correlation between serum IL-18 and islet cell antibody (ICA) and C-peptide levels,
but not between serum IL-18 and HbA1C, insulin and glucose in T1DM. Serum IL-18 levels
also correlated positively with serum IL-12 levels. Serum IL-18 levels was significantly high‐
er in patients with DKA than those in patients without DKA while C-peptide levels were
markedly lower in patients with DKA. These results point that serum IL-18 levels are elevat‐
ed and correlated with C-peptide levels and ICA in patients with T1DM, with marked in‐
crease in T1DM with DKA. Clinicans should be aware of the risk of DKA in diabetic patients
with high serum IL-18 [47]. The procoagulant and inflammatory states may be due to non‐
specific phenomena of stress and may partially explain the association of hyperglycemic cri‐
ses with a hypercoagulable state [48].
4. Precipitating factors
A careful search for precipitating factors should be made, as correction of these contributes
to improved outcomes and less frequent recurrences.
The most common precipitating factor in the development of DKA is infection [37,49,50] in‐
cluding viral syndromes, urinary tract infections, pelvic inflammatory disease, pneumonia,
mucormycosis, malignant otitis externa (with pseudomonas aeruginosa), periodontal ab‐
scess and dental infection [51]. Other precipitating factors include discontinuation of, or in‐
adequate insulin therapy, acute pancreatitis, myocardial infarction, stroke, major trauma
and other severe/acute illnesses and drugs [30,32,37]. New-onset T1DM or discontinuation
of insulin in T1DM frequently leads to the development of DKA. In young patients with
T1DM, psychological problems complicated by eating disorders may be a contributing fac‐
tor in 20% of recurrent ketoacidosis. In younger patients fear of weight gain and hypoglyce‐
mia, stresss of chronic disease may lead to insulin omission.
In the past, before the improvement in technology and sufficient education of patients con‐
tinuous subcutaneous insulin infusion devices had also been associated with an increased
frequency of DKA [52]; nowadays the incidence of DKA appears to have reduced in pump
users [53]. Additional prospective studies are needed to document reduction of DKA inci‐
dence with the use of continuous subcutaneous insulin infusion devices [54].
Drugs that  affect  carbohydrate metabolism, such as corticosteroids,  thiazides,  sympatho‐
mimetic agents and pentamidine may precipitate the development of DKA [10].  The as‐
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sociation  between  antipsychotic  drugs,  especially  with  atypical  antipsychotics  and
hyperglycemia and even DKA have been reported in some cases [55,56].  Arefi  et  al.  re‐
ported the first case of DKA due to nalidixic acid overdosage [57].  It  has been available
for the treatment of urinary tract infections for many years [58]. There are reports of hy‐
perglycemia, convulsions and glycosuria in overdosage of nalidixic acid [58-61]. Interfer‐
on-alpha  (IFN-α),  a  natural  protein  with  anti-viral,  anti-proliferative  and
immunomodulatory effects is routinely administered in chronic hepatitis C (CHC). Clas‐
sical IFN-α has been correlated with the development of a variety of autoimmune disor‐
ders  including  Hashimoto  thyroiditis,  immune-mediated  thrombocytopenia,  hemolytic
anemia,  psoriasis,  rheumatoid  arthritis,  systemic  lupus  erythematosus,  primary  biliary
cirrhosis and sarcoidosis. It is unclear whether IFN-α treatment is associated with the de‐
velopment of T1DM. The prevalence of diabetes mellitus development in patients receiv‐
ing classical IFN-α for CHC is very low ranging from 0.08% to 0.7% [62,63]. Fabris et al.
reviewed 9 relative studies; the prevalence of pancreatic auto-antibodies appeared to rise
from 3% to 7% prior to and following initiation of IFN-α treatment [64]. Soultati et al. re‐
ported a 38 year-old female patient developed simultaneously DKA and hyperthyroidism
5 months following initiation of treatment with pegylated IFN-α and ribavirin for CHC.
High titers  of  glutamic  acid  decarboxylase,  antinuclear  and thyroid  (thyroid  peroxidase
and thyroglobulin)  antibodies  were  detected  [65].  Until  2005,  35  cases  of  IFN-α related
T1DM had been reported in the medical literature [64,66-69]. DKA was reported in a few
classical  IFN-α  related  cases  [70-73],  in  three  pegylated  IFN-α  related  cases  [65,74,75].
The development of DKA and the permanent insulin dependency may be related with a
rapidly developing T helper-1-mediated pathogenic mechanism [72]. Tacrolimus, a rever‐
sible calcineurin inhibitor, is known for its diabetogenic potential. The incidence of diabe‐
tes  is  less  frequent  among  the  patients  of  nephrotic  syndrome in  comparison  to  organ
transplant recipients. DKA is even rarer. Sarkar et al.  reported in a 12-year-old girl with
steroid resistant nephrotic syndrome, DKA as the first presentation of new onset tacroli‐
mus  induced  transient  T1DM  despite  a  lower  dose  range  and  low  trough  level  of  the
drug is being [76].
Cocaine abuse causes recurrent DKA with several mechanisms, including therapeutic non‐
compliance, stimulation of adrenal release of epinephrine and norepinephrine and increased
release of other counter regulatory hormones [30,77]. Cytomegalovirus infection [78,79],
protease inhibitor treatment [80,81] and highly active antiretroviral therapy (via immune re‐
storation) may precipitate DKA in HIV-infected patients [82].
5. Diagnosis
5.1. History and physical examination
The acute DKA episode in T1DM evoluation should be done rapidly.  The symptoms of
poorly  controlled  diabetes  may  be  present  for  several  days,  but  the  metabolic  changes
typical  of  ketoacidosis  usually  occurs  within a  short  time (typically  24  h).  Occasionally,
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the entire symptomatic presentation may evolve or develop more acutely and the patient
may present  with DKA with no prior  clues or  symptoms.  For DKA, the typical  clinical
findings  includes  a  history  of  polyuria,  polydipsia,  weight  loss,  vomiting,  dehydration,
weakness and mental status change. Physical examination may include poor skin turgor,
Kussmaul  respirations,  tachycardia  and  hypotension.  Mental  status  can  vary  from  full
alertness  to  profound  lethargy  or  coma  [10,37].  The  symptoms  and  physical  signs  of
DKA are listed in Table 1.
MANIFESTATIONS OF DIABETIC KETOACIDOSIS
Symptoms
Nausea / vomiting
Thirst / polyuria
Abdominal pain
Shortness of breath
Physical findings
Tachycardia
Dry mucous membranes / reduced skin turgor
Dehydration / hypotension
Tachypnea / Kussmaul respirations
Abdominal tenderness
Lethargy / obtundation / cerebral edema / possibly coma
Table 1. The symptoms and physical signs of DKA
Although infection is a common precipitating factor for DKA, patients can be normothermic
or even hypothermic. Severe hypothermia, if present, is a poor prognostic sign and could be
fatal. The major complications of hypothermia are acute renal failure, aspiration pneumonia,
rhabdomyolysis, acute respiratory distresss syndrome and acute pancreatitis [83]. The
mechanism of hypothermia complicated by DKA is unclear, but the inability of glucose to
endocytose due to insulin deficit which leads to a lack of substrate for cellular heat produc‐
tion has been proposed [84]. A characteristic elevated J point on the electrocardiogram
(ECG) (Osborn wave) may be observed when markedly hypothermia occurs [85-87]. The
thermoregulatory system could be impaired in diabetic patients with autonomic neuropathy
and reduced muscle mass or adipose tissue related with malnutrition. Thus, become prone
to hypothermia under certain conditions [88,89].
Nausea, vomiting, diffuse abdominal pain are frequent in patients with DKA (50%) [90]. Ab‐
dominal pain on presentation could be a result of the DKA or an indication of a precipitat‐
ing cause of DKA, particularly in younger patients or in the absence of severe metabolic
acidosis [91,92]. Further evaluation is necessary if this complaint does not resolve with suc‐
cessfull treatment, because this may indicate other underlying complications.
5.2. Laboratory findings
The initial  laboratory evaluation should include determination of  plasma glucose,  blood
urea nitrogen, creatinine, electrolytes (with calculated anion gap),  osmolality,  serum and
urinary  ketones  and  urinalysis,  as  well  as  initial  arterial  blood  gases  and  a  complete
blood  count  [93].  If  laboratory  measurement  of  serum  potassium  is  delayed  an  ECG
should  be  performed  for  baseline  evaluation  of  potassium  status  [94,95].  An  increased
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WBC count is  response to stress  is  characteristic  of  DKA and is  not  indicative of  infec‐
tion. If there is evidence of infection, chest X-ray and urine, sputum, throat or blood cul‐
tures should also be obtained [93].
The severity of DKA is classified as mild, moderate, or severe based on the severity of meta‐
bolic acidosis (blood pH, bicarbonate, and ketones) and the presence of altered mental status
as shown in Table 2.
>12>12>10Anion gap ‡
Stupor/comaAlert/drowsyAlertMental status
VariableVariableVariableEffective serum 
osmolality †
PositivePositivePositiveSerum ketone *
PositivePositivePositiveUrine ketone *
<10 10 to <15 15–18 Serum bicarbonate
(mEq/l) 
<7.00 7.00 to <7.24 7.25–7.30 Arterial pH
Severe (plasma glucose >250 
mg/dl)
Moderate (plasma glucose
>250 mg/dl)
Mild (plasma glucose >250 
mg/dl)
DKA
*Nitroprusside reaction method.
†Effective serum osmolality: 2[measured Na+ (mEq/l)] + glucose (mg/dl)/18.
‡Anion gap: (Na+) − [(Cl− + HCO3− (mEq/l)].
Table 2. Classification of DKA
One of the major laboratory findings in DKA is the elevation of total blood ketone concen‐
tration. Assessment of increased ketonemia is usually performed by the nitroprusside reac‐
tion which provides a semiquantitative estimation of acetoacetate and acetone levels. The
nitroprusside test (both in urine and in serum) is highly sensitive, but it does not recognize
the main metabolic product in ketoacidosis; beta-hydroxybutyrate. In conclusion this assay
is insufficient to determine the severity of ketoacidosis [10,31]. Measurement of serum ß- hy‐
droxybutyrate may be an alternative to determine ketoacidosis [96). Ketoacids cause an in‐
creased anion gap metabolic acidosis. The anion gap is calculated by subtracting the sum of
chloride(Cl) and bicarbonate (HCO3) concentration from the sodium (Na) concentration:
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[Na - (Cl +HCO3)]. A normal anion gap is between 7 and 9 mEq/l and an anion gap 10–12
mEq/l indicates the presence of increased anion gap metabolic acidosis [10].
In  clinical  trials  mixed acid–base  disorders  have been showed in  DKA [97,98],  but  it  is
very rare  the presentation of  DKA with alkalaemia.  The first  case has been reported in
1970, defined as ‘diabetic ketoalkalosis’ [99] and it was followed by other case reports.
The factors related with alkalemia in DKA were; recurrent vomiting which causes hydro‐
gen  and  chloride  ion  loss  (autonomic  neuropathy  such  as  delayed  gastric  emptying
might have been related to recurrent vomiting), alkali ingestion and contraction alkalosis
due  to  dehydration  and/or  diuretic  use  [100].  Treatment  of  diabetic  ketoalkalosis  does
not differ from that of pure DKA.
Hyperglycemia is a key diagnostic criterion of DKA; but plasma glucose level varies in a
wide range on admission. Recent studies have reported from normal or near normal [101] to
elevated [31,3] hepatic glucose production rates. This factor possibly contributes to the wide
range of plasma glucose levels in DKA that are independent of the severity of ketoacidosis
[96]. In contrast to this 10% of the DKA patients presents with so-called ‘true euglycemic
DKA’ [blood glucose <200 mg/dl (11.1 mmol/l)] [102]. Due to nausea or vomiting caused by
a precipitating illness or by worsening ketoacidosis itself, a decrease in caloric intake occurs.
If patients continue to take sufficient amounts of insulin in this situation may maintain eu‐
glycemia. But ketone body formation cannot be stopped, so they present as DKA accompa‐
nied with only mild elevations of blood glucose or normoglycemia [103-105]. Euglycemic
DKA can be associated with other conditions such as; near total glycogen depletion
[106,107], accelerated lipolysis [108] and free fatty acid production [109], less effectiveness of
insulin suppressing lipolysis and ketogenesis during fasting and when there is sufficient cir‐
culating fluid volume to maintain glucose excretion [110]. In women with diabetes, pregnan‐
cy is also a condition that is associated with euglycemic ketoacidosis [111,112] as pregnancy
is considered to be a state of accelerated starvation [113] with increased lipolysis and ketone
body production in the presence of increased insulin insensitivity [114].
At presentation leukocytosis with cell counts in the 10,000 –15,000 mm3 range is commonly
seen in DKA and may not be indicative of an infection. But leukocytosis with cell counts
25,000 mm3 may indicate infection and require further evaluation [115]. In ketoacidosis, leu‐
kocytosis may be correlated to elevated levels of cortisol and norepinephrine which is attrib‐
uted to stress [116].
On admission serum sodium is usually low because of the osmotic flux of water from the
intracellular to the extracellular space as a result of hyperglycemia. An increased or even
normal serum sodium concentration in the presence of hyperglycemia indicates severe de‐
gree of free water loss. To assess the severity of sodium and water deficit, serum sodium
may be corrected by adding 1.6 mg/dl to the measured serum sodium for each 100 mg/dl of
glucose above 100 mg/dl [10,31]. In the calculation of effective osmolality, [sodium ion
(mEq/l) x 2 + glucose (mg/dl)/18], the urea concentration is not taken into account because it
is freely permeable and its accumulation does not induce major changes in intracellular vol‐
ume or osmotic gradient across the cell membrane [10].
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Serum potassium concentration may be increased because of an extracellular shift of potassi‐
um caused by insulin deficiency, hypertonicity and acidemia [117]. However, patients have
severe total-body potassium deficiency. Treatment could be lowers serum potassium con‐
centration and trigger cardiac arrhythmia. So patients with low normal or low serum potas‐
sium concentration should be monitored closely. If necessary appropriate potassium
replacement should be done [93].
Insulin mainly affects glucose metabolism, but also protein and lipid metabolism. In the lit‐
erature there are many cases of DKA presented with severe hyperlipidemia [118,119]. In pa‐
tients with newly diagnosed T1DM presenting with DKA there is an absolute insulin
deficiency that causes increased lipolysis and free fatty acid accumulation to the liver, de‐
creased in utilization and excretion which results with hyperlipidemia. Severe hypertrigly‐
ceridemia can complicate DKA by the development of pancreatitis. As it is related with
increased morbidity and mortality, clinicians must be aware of this complication. Children
under the age of 5 years presenting with DKA have a higher rate of mortality. Therefore,
these should be monitored for hyperlipidemia and if there is clinical evidence, for pancreati‐
tis [120-123]. Pseudonormoglycemia [124] and pseudohyponatremia [125] may occur in
DKA in the presence of severe chylomicronemia.
On the admission in patients with DKA, serum phosphate level is usually elevated because
of an extracellular shift of phosphate caused by insulin deficiency, hypertonicity and in‐
creased catabolism. Thus, serum concentration does not reflect an actual body deficit
[31,126,127]. Typical total body deficits of water and electrolytes in DKA are seen in Table 3.
1-2Ca + + (mEq/kg)
1-2Mg + + (mEq/kg)
5-7PO4 (mmol/kg)
3-5K + (mEq/kg)
3-5Cl ­ (mEq/kg)
7-10Na +  (mEq/kg)
100Water (ml/kg)*
6Total water (L)
Typical deficits
Table 3. Typical total body deficits of water and electrolytes in DKA (*Per kg of body weight)
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Increased amylase and lipase has been reported in 16-25 % of patients with DKA. The mech‐
anism of elevated enzymes in DKA remains unclear. Amylase elevations could be related
with subtle injury to pancreatic acinar cells which causes release of this enzyme to the circu‐
lation, release of salivary gland amylase or suboptimal excretion in the urine [128]. There is
little correlation between the presence, degree or isoenzyme type of hyperamylasemia and
the presence of gastrointestinal symptoms (nausea, vomiting, and abdominal pain) or pan‐
creatic imaging studies [129]. Increase in lipase may be related with release of nonpancreatic
lipolytic enzymes into the circulation due to malignant tumors, to acute cholecystitis or
esophagitis. Other possible mechanism are; renal insufficiency, delayed blood withdrawal,
hypertriglyceridemia or subclinical pancreatitis [130]. Pancreatic enzyme levels reach a peak
12-24 hours after initiation of treatment for DKA [131]. Hyperlipasemia is less reliable for
diagnosing acute pancreatitis, but elevated lipase is more spesific.
5.3. Differential diagnosis
Other causes of metabolic acidosis and ketosis must be differentiated from DKA. Differan‐
tial diagnosis of DKA can be seen in Table 4.
------++Glycosuria
NNNNMİldUric acid
NNNNOsmolality
SlightSlightAnion gap
NNSlight to
moderate
NNSlightTotal 
plasma
ketones
N orNor NNNNPlasma
glucose
Mİld
NPh
Salicylate
intoxication
Methanol or
ethylenglycol
intoxication
Alcholic
ketosis
Uremic
acidosis
Lactic
acidosis
Starvation
or high fat
intake
DKA
*Acetest and Ketostix measure acetoacetic acid only, thus misleading low values may be
obtained because the majority of ‘ketone bodies’ are ß­hydroxybutyrate. 
*(Data adapted from reference 10)
Table 4. Differantial diagnosis of DKA
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Acute renal failure can be seen in ~5-7% of all adult hospitalizations [132,133]. It shares the
common feature of an increased anion gap metabolic acidosis but can be easily differentiat‐
ed from DKA by the absence of hyperglycemia or ketonemia. On the other hand, severe
DKA can lead to prerenal azotemia and secondary acute kidney injury [134,135].
Severe uremic acidosis, characterized by an extremely high blood urea nitrogen, often >200
mg/dL (71.4 mmol/L) and creatinine >10 mg/dL (884 umol/L) causes acidosis via retention of
anionic solutes in the patient with chronic kidney disease. The pH and anion gap can be
found usually mild abnormal, however blood sugar is typically normal. Severe uremia typi‐
cally occurs when creatinine clearance falls to <10 mL/min (0.1669 ml/s) in irreversible renal
disease [136].
Lactic acidosis occasionally contributes to metabolic acidosis in patients hospitalized for ei‐
ther uncomplicated diabetes or DKA [137]. The main reason of lactic acidosis is tissue hypo‐
xia [138]. It occurs in the setting of decreased tissue oxygen delivery which triggers non-
oxidative metabolism of glucose to lactic acid. When co-existent with DKA, the anion gap
typically exceeds that attributable to lactate alone. If lactic acidosis, with a serum lactate ≥5
mmol/L (45 mg/dL), occurs accompanied with DKA or hyperosmolar hyperglycemic state,
severe volume depletion affects cardiac output negatively and also pre-existent cardiovascu‐
lar disease increases this risk. Underlying liver disease with reduced lactate clearance and
sepsis may also contribute more frequent/severe lactic acidosis in hyperglycemic emergen‐
cies. For main therapy it should be performed to optimise tissue perfusion and to treat un‐
derlying conditions [17,136].
When there is insufficient carbohydrate availability, starvation ketosis may occur by result
of physiologically appropriate lipolysis and ketogenesis to provide fuel substrates. Blood
glucose and arterial pH are found to be usually in normal level and the anion gap is at most
mildly elevated. Although ketonuria may be apparent in urine analysis, modest ketonemia
is typical in blood examination [17,136].
Chronical alcohol abuse may be the reason of alcoholic ketosis for ethanol is the predomi‐
nant caloric source for days or weeks. Ketosis happens in sudden decrease of alcohol and
caloric intake. Patients are usually present in normoglycemic or hypoglycemic state on sub‐
mission, although some have rarely mild hyperglycemia [136].
Toxic ingestions sometimes need to be differentiated and history of the patients with labora‐
tory studies may help for the differantial diagnosis. Salicylate, methanol and ethylene glycol
each produce an increased anion gap metabolic acidosis without hyperglycemia or ketosis.
Methanol and ethylene glycol will also cause a serum osmolal gap [17,136]. Measurement of
suspicious drug/toxin concentrations with high index of suspicion, usually confirms the di‐
agnosis of acute intoxication [139-142].
If there are some gastrointestinal or renal losses for any reason, non-anion gap metabolic
acidosis  may  occur.  It  is  characterized  by  a  low  serum  bicarbonate  concentration  with
subsequent chloride retention. Diarrhea and renal tubular acidosis are frequent causes of
this condition.  Carbonic anhydrase inhibitor therapy,  rapid dilution of  plasma bicarbon‐
ate by infused saline may be considered as the other varying reasons [143,144]. DKA can
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be  easily  differentiated  from  this  condition  by  the  presence  of  an  increased  anion  gap
and hyperglycemia. In complicated diabetics,  especially in diabetic nephropathy, if  there
is  hypoalbunemia,  it  can  affect  the  apparent  anion  gap,  since  albumin  is  negatively
charged  protein  contibuting  50-60%  to  the  normal  anion  gap.  If  albumin  is  below  the
normal value of 4 g/dL (40 g/L), the calculated anion gap should be corrected by adding
2.5  for  every  10  g/L  (1  g/dL)  to  determine  whether  excessive  abnormal  anions  are
present [145-147].
6. Treatment
Successful treatment of DKA requires correction of dehydration, hyperglycemia and elec‐
trolyte imbalances, identification of comorbid precipitating events and above all, frequent
patient  monitoring.  Protocols  for  the management of  patients  with DKA is  summarized
in Fig. 2 [10].
6.1. Fluid therapy
The most  important  initial  therapeutic  intervention is  fluid replacement followed by in‐
sulin administration. DKA is a volume depletion state with water deficit, varying widely
but averaging 6 L [51]. Initial fluid therapy is directed toward expansion of the intravas‐
cular, interstitial and intracellular volume (all of which are reduced in hyperglycemic cri‐
ses),  to establish tissue perfusion for insulin to reach cells  [148] and restoration of renal
perfusion. The goal of fluid resuscitation is to replace half of the estimated water deficit
over the first 12-24 hours and adding for the ongoing losses (eg: vomiting) [51]. Replace‐
ment  fluids  may  decrease  the  blood  glucose  by  up  to  23%  because  of  increased  renal
perfusion and loss of glucose in urine [149] Hyperglycemia can reduce serum sodium by
causing an osmotically  driven shift  of  water  from intracellular  to  extracellular  compart‐
ments.  In the previous estimated models;  each 5.5 mmol/L (100 mg/dL) increase in glu‐
cose above normal resulted in a decrease of 1.6 mmol/L (1.6 mEq/L) in measured serum
sodium [150],  Hillier  et  al.  suggested that  2.4  mmol/L (2.4  mEq/L)  per  5.5  mmol/L (100
mg/dL) glucose increase is more accurate [151].
The  initial  fluid  of  choice  is  isotonic  saline,  generally  given  for  the  first  4  hours  of
therapy  (Table  4).  Subsequent  choice  for  fluid  replacement  depends  on  hemodynamics,
the  state  of  hydration,  serum  electrolyte  levels  and  urinary  output.  Fluid  resuscitation
should  be  individualized  according  to  the  patient’s  degree  of  dehydration,  mental  sta‐
tus  and  underlying  diseases  such  as  congestive  heart  failure  or  renal  failure  [51].  Glu‐
cose,  an  osmotic  diuretic,  may  produce  a  high  urine  output  even  in  severely
dehydrated  patients.  The  threshold  for  glycosuria  in  healthy  adults  occurs  at  plasma
glucose  concentration  of  approximately  180  mg/dL  (9.99  mmol/L),  though  adults  with
long-standing  diabetic  nephropathy  may  have  considerably  higher  thresholds.  As  a  re‐
sult,  urine  output  should  not  be  considered  a  reliable  predictor  of  volume  status  in
hyperglycemic states  [152].
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IV Fluids
Determinde hydration
status
Severe
hypovolemia
Cardiogenic
shock
Administer
0,9% NaCl
(1.0 L / hr)
Hemodynamic
monitoring
Pressors
Evaluate serum
corrected Na+
High Normal Low
0,9% NaCl
(250-500 ml//hr)
Depending on hydration state
0,45% NaCl
(250-500 ml//hr)
Depending on hydration state
When serum glucose reaches 200 mg/dl change to
5% dextrose with 0,45% NaCl or 0,9% NaCl
at 150-200 ml/hr
Bicarbonate
pH≥6.9
No HC3-
pH<6.9
100 mmol in
400ml H2O +20 mEq KCL infuse
for 2 hrs
Repeat every 2
hours
until pH≥7
Insulin regular
0,1 U/kg/Bwt
as IV bolus
0,14 U/kg/Bwt/hr
as IV continious
insulin infusion
0,1 U/kg/hr
IV continious
insulin infusion
If serum glucose does not fall by at least
10% in first hr, give 0,14 U/kg as IV bolus,
then continue previous treatment
When serum glucose reaches 200 mg/dl,reduce
regular insulin infusion to 0,02-0,05 U/kg/hr
IV or give rapid-acting insulin at 0,1U/kg SC
every 2 hrs. Keep serum glucose between
150-200 mg/dl until resolution
After resolution of DKA and when patient is able to eat, initiate SC multidose
insulin regimen. To transfer from IV to SC, continue insulin infusion for 1-2 hr
after SC insulin begin to ensure adequate plasma insulin levels. In ınsulin naive
patients, start at 0,5 U/kg to 0,8 U/kg body weight per day and
adjust ınsulin as needed
Potassium
Establish adequate renal
function (urine output ~50 ml/hr)
K+<3,3 mEq/L
Hold insulin and
give 20-30 mEq/hr
until K+> 3,3 mEq/L
K+<5,2 mEq/L
Do not give K+
but check serum K+
every 2 hours
K+= 3,2 – 5,2 mEq/L
Give 20-30 mEq K+ in each liter
of IV fluid to keep serum K+
between 4 – 5 mEq/L
Figure 2. Protocols for the management of patients with DKA (Data adapted from reference 10)
Hours Volume
1st hour
2nd hour
3rd-5th hours
6th-12th hours
1,000 – 2,000 mL
1,000 mL
500 – 1,000 mL/hour
250 – 500 mL/hour
Table 5. Suggested average initial replacement rate of fluid in DKA (after hemodynamic resuscitation with normal
saline when indicated)
Many guidelines recommend initial fluid resuscitation with colloid in hypotensive patients.
However, the hypotension results from a loss of electrolyte solution and it is more physio‐
logical to replace with crystalloid. A recent Cochrane review did not support the use of col‐
loid in preference to crystalloid fluid [153]. In the absence of cardiac compromise, isotonic
saline (0.9% NaCl) is infused at a rate of 15–20 ml kg/body wt/h or 1–1.5 L during the first
hour. In general, 0.45% NaCl infused at 250–500 ml/hour is appropriate if the corrected se‐
rum sodium is normal or elevated; 0.9% NaCl at a similar rate is appropriate if corrected se‐
rum sodium is low (Fig. 2). That total fluid administered should not exceed 4 L/m²/24 hour
for fear of causing cerebral edema is most often the mainstay of therapy in many pediatric
critical care unit protocols [154,155]. Successful treatment with fluid replacement can be
evaluate by hemodynamic monitoring (improvement in blood pressure), measurement of
fluid input/output, laboratory values and clinical improvement. In patients with renal or
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cardiac failure, monitoring of serum osmolality and frequent assessment of cardiac, renal
and mental status must be performed during fluid resuscitation to avoid iatrogenic fluid
overload [10,37,148]. During treatment of DKA, hyperglycemia is corrected faster than ke‐
toacidosis. The mean duration of treatment until blood glucose is <250 mg/dl and ketoacido‐
sis (pH>7.30; bicarbonate >18 mmol/l) is corrected is 6 and 12 hours [36,156]. Once the
plasma glucose falls to <200-250 mg/dL (11.1-13.88 mmol/L), 5% dextrose should be added
to replacement fluids to allow continued insulin administration until ketonemia is control‐
led while at the same time avoiding hypoglycemia [93,135]. In hypotensive patients, aggres‐
sive fluid resuscitation with isotonic saline should be continued until blood pressure
normalized [51].
6.2. Insulin therapy
Insulin lowers the serum glucose concentration (by decreasing gluconeogenesis and glyco‐
genolysis, increasing tissue glucose uptake) and arrests ketone production (by reducing lip‐
olysis and glucagon secretion). The most important point in the treatment of DKA involves
insulin administration. There was major concern about; physiologic or low dose insulin
therapy was superior to pharmacologic dose regimen and the administration of regular in‐
sulin via continuous intravenous infusion or by frequent subcutaneous or intramuscular in‐
jections [10,157-160]. Several randomized controlled studies have shown that physiologic or
low dose insulin therapy was superior to pharmacologic dose regimen and low-dose insulin
therapy is effective regardless of the route of administration in DKA [118,159,160]. In clinical
practice most patients are treated with low dose, intravenous regular insulin until resolution
of DKA [30]. The administration of continuous intravenous infusion of regular insulin is
preferred because of its short half-life and easy titration and the delayed onset of action and
prolonged half-life [107,127,160].
Previous treatment algorithms have recommended the administration of an initial intrave‐
nous bolus of regular insulin (0.1 unit/kg) followed by the infusion of 0.1 unit/kg/h [10,17],
but a recent prospective randomized study showed that a bolus dose is not required if pa‐
tients are given hourly insulin infusion at 0.14 unit/kg body weight [161]. Low-dose insulin
infusion protocols decrease plasma glucose concentration at a rate of 50–75 mg/d/ h. If plas‐
ma glucose does not decrease by 50–75 mg in the first hour, the insulin infusion should be
increased every hour until a steady glucose decline is achieved. When the plasma glucose
reaches 200 mg/dl in DKA, the insulin infusion rate may decrease to 0.02–0.05 units/kg/h, at
the same time dextrose should be added to the intravenous fluids for avoiding hypoglyce‐
mia. The rate of insulin administration or the concentration of dextrose may need to be ad‐
justed to maintain glucose values between 150 and 200 mg/dl until DKA resolved [90].
Resolution of ketoacidosis includes these criteria; a blood glucose <200 mg/dl and two of the
following criteria: a serum bicarbonate level >15 mEq/l, a venous pH >7.3, and a calculated
anion gap in normal range. Once hyperglycemia is corrected, 12-24 hours of intravenous in‐
sulin treatment is sufficient to clear ketones from the circulation [51].
Subcutaneous rapid-acting insulin analogs (lispro and aspart) offer an efficacious and cost-
effective alternative to continuous intravenous infusions in the treatment of DKA [162-164].
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Umpierrez et al. used subcutaneous rapid-acting insulin (insulin lispro or aspart) 0.2
units/kg initially followed by 0.1 unit/kg every hour or an initial dose of 0.3 units/kg fol‐
lowed by 0.2 units/kg every 2 hours, until blood glucose is ≤ 250 mg/dL; the insulin dose is
then decreased by half (to 0.05 or 0.1 unit/kg, respectively) every 1-2 hours until resolution
[162,163]. There were no differences in length of hospital stay, total amount of insulin need‐
ed for resolution of hyperglycemia or ketoacidosis. Patients treated with insulin analogs
were managed in the open medical wards which reduced cost of hospitalization by 30%
[162-164]. This approach is not widely used for many reasons, including titration difficulties
with longer half-life preparations, requirement for hourly nursing interventions and lack of
staff experience compared to that with standard insulin infusions. However, until these
studies are confirmed outside the research arena, patients with severe DKA, hypotension,
anasarca or associated severe critical illness should be managed with intravenous regular in‐
sulin in the intensive care unit [93].
In patients younger than 4 years of age there is a prolonged time lag for plasma glucose lev‐
els to reach 12 to 14 mmol/L, because young children and adolescents who have high
growth velocity and higher levels of the human growth hormone, a diabetogenic hormone.
In addition to this, patients with fever or infections and higher metabolic requirements may
need 15% to 20% more insulin than the usual dose [165].
In rare cases of patients with allergy to human insulin presenting with hyperglycemic crisis,
desensitization to human insulin may be performed before treatment with human insulin. A
recent case report documented the successful treatment of a woman with allergy to human
insulin and its analogs with continuous subcutaneous infusion of human insulin [166].
6.3. Potassium
Despite  a  total  body  potassium  deficit  resulting  from  the  glycosuric  osmotic  diuresis,
mild-to-moderate  hyperkalemia  is  common  in  patients  with  hyperglycemic  crises  upon
initial  presentation  because  of  proteolysis,  acidosis,  and  insulin  deficiency  [10,167].  In‐
sulin  therapy,  correction  of  acidosis  and  volume  expansion  decrease  serum  potassium
concentration [10].
Occasionally patients with DKA may present with significant hypokalemia, in which case
insulin therapy should be delayed until potassium concentration is corrected to >3.5 me‐
quiv./l to avoid arrhythmias and respiratory muscle weakness [168,169]. To prevent hypoka‐
lemia, potassium replacement is initiated after serum levels fall below the upper level of
normal for the particular laboratory (5.0-5.2 mEq/l) in patients without renal impairment.
The treatment goal is to maintain serum potassium levels within the normal range of 4–5
mEq/l. Generally, 20–30 mEq potassium in each liter of infusion fluid is sufficient to main‐
tain serum potassium concentration within the normal range but additional doses may be
necessary [10,30].
The rare patient with severe hyperkalemia (>6.0 mEq/l) on admission with concomitant elec‐
trocardiographic changes may benefit from bicarbonate therapy [170].
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6.4. Bicarbonate therapy
The hepatic metabolism of free fatty acids generates ketoanions, such as beta-hydroxybuty‐
rate and acetoacetate [171,172]. Impaired tissue perfusion due to volume contraction and the
adrenergic response to the often severe underlying precipitating illness result in lactate pro‐
duction [173]. Acute kidney injury leads to accumulation of other unmeasured anions, such
as sulphate, urate and phosphate [174]. All these, together with hyperchloremia which pre‐
dominates during the recovery phase of DKA [175], contribute to the development of acide‐
mia, which often is severe [176,177].
Metabolic acidemia can impair myocardial contractility, reduce cardiac output, affect oxyhe‐
moglobin dissociation and tissue oxygen delivery, inhibit intracellular enzymes, such as
phosphofructokinase, alter cellular metabolism, and result in vital organ dysfunction
[178-181]. In the past, therapy in DKA has placed importance on the rapid reversal of acide‐
mia. But based on currently available evidence, several deleterious effects of bicarbonate
therapy have been reported, such as increased risk of hypokalemia, decreased tissue oxygen
uptake, cerebral edema and development of paradoxical central nervous system acidosis
[182]. The use of bicarbonate in DKA remains a controversial subject.
Since severe acidosis may be associated with adverse effects, patients with pH <6.9 or when
pH is <7.1 and hemodynamic instability or hyperkalemic electrocardiographic changes are
present [93,135], bicarbonate should be given. A choice is to give 100 mmol sodium bicar‐
bonate (two ampules) in 400 ml sterile water with 20 mEq KCI at a rate of 200 ml/h for 2
hours. If the pH is stil <7.0 after infusion, we recommend repeating infusion every 2 hours
until pH reaches >7.0 [17,93]. Potassium replacement should be considered before adminis‐
tering bicarbonate or KCL should be added in the bicarbonate solution at 40 mmol (40 mEq)
KCl/L to avoid precipitous hypokalemia [93,135].
6.5. Phosphate
In  patients  with  DKA  there  is  about  1  mmol/kg  body  weight  phosphate  depletion.  At
presentation  serum  phosphate  levels  are  usually  normal  or  elevated.  But  with  insulin
therapy  these  levels  rapidly  decrease  [90,132].  Randomized  studies  showed  that  phos‐
phate  replacement  have  no  any  additional  benefit  on  the  clinical  outcome  [126,183]
and  in  contrast,  phosphate  replacement  may  trigger  hypocalcemia  and  hypomagnese‐
mia [183,184].  Hypophosphatemia can cause hemolysis,  refractory acidosis,  reduced car‐
diac  output,  respiratory  muscle  weakness,  rhabdomyolysis,  central  nervous  system
depression,  seizures,  coma  or  acute  renal  failure.  Careful  phosphate  replacement
should  be  planned  to  the  patients  with  these  findings  and  severe  hypophosphatemia
(serum phosphate <1 mg/dL) [10,90,132].  In severe deficiency,  the amount,  added to in‐
travenous  replacement  fluids  can  be  20–30  mEq/l  potassium phosphate.  Secure  replace‐
ment  rate  that  can  correct  hypophosphatemia  is  4.5  mmol/h  (1.5  ml/h  of  K2  PO4)
[185].  In  less  severe  deficiencies  80-110  mmol  (2.5-3.5  g)  daily  in  2-3  divided  doses  or‐
al  phosphate can be given [93,135,186].
Type 1 Diabetes266
6.6. Transition to subcutaneous insulin
When DKA has resolved, patients who are appropriate for oral intake can be started on a
multiple dose insulin regimen with a long acting insulin (e.g. glargine or detemir) to cover
basal insulin requirements and short/rapid acting insulin (lispro, aspart or glulisine) given
before meals to control plasma glucose. To ensure adequate plasma insulin levels and to
avoid hyperglycemia and ketonemia intravenous insulin infusion should be continued for
1–2 hours after the subcutaneous insulin is given. Patients who are inappropriate for oral in‐
take the treatment should be continued with an infusion of intravenous fluids and insulin
[10,17,49,93,187]. A multiple-dose subcutaneous combination regimen is preferred, as it is
related with less hypoglycemia and provides a better physiologic pattern of control than
other regimens. In insulin-naїve patients, a multidose insulin regimen should be started at a
dose of 0.5-0.8 units/kg body weight per day. Patients with known diabetes, whose blood
glucose monitoring are in the normal ranges before DKA, may start with dose of insulin
they are receiving [160].
In the past human insulin (NPH and regular) were usually given in two or three doses per
day. With the development of new analogue insulins, basal-bolus regimens with basal (glar‐
gine and detemir) and rapid-acting (lispro, aspart, or glulisine) insulin treatments became a
major concern in the treatment of DKA. A prospective randomized trial compared with a
split mixed regimen of NPH plus regular insulin twice daily treatment and a basal-bolus
regimen, including glargine once daily and glulisine before meals following the resolution
of DKA. Glycemic control were similar between the two groups but the study showed that
treatment with basal-bolus insulin regimen was associated with a lower rate of hypoglyce‐
mic events (15%) than the rate in those treated with NPH and regular insulin (41%). This
trial showed that analogue insulins may offer a more physiologic effect [156].
6.7. Somatostatin therapy in the management of resistant diabetic ketoacidosis
As a  inhibiting  hormone for  counterregulatory  hormones,  somatostatin  may be  used in
the treatment of  DKA. Somatostatin analogues have been successfully used in the treat‐
ment of diabetes associated autonomic neuropathy and they have also been shown to de‐
crease  the  requirements  for  insulin  [188,189].  Continuous  subcutaneous  octreotide
infusion suppresses counterregulatory hormones,  increases insulin-mediated glucose me‐
tabolism by enhancing glucose storage and reduces energy expenditure [189].  There are
limiting data in the literature about somatostatin use in DKA. Diem et al.  were assessed
preventive  effects  of  octreotide  on  diabetic  ketogenesis  during  insulin  withdrawal.  Oc‐
treotide led to a marked suppression of beta-hydroxybutyrate, acetoacetate and glucagon
levels and an associated diminution of bicarbonate consumption and the fall in pH [190].
Anthony et al. reported a case of DKA with glucagonoma who was unresponsive to con‐
ventional  therapy and treated  with  octreotide  [191].  In  conclusion,  for  patients  who do
not  respond  to  conventional  DKA  treatment,  somatostatin  could  be  added  to  therapy.
More data and further randomized controlled clinical trials should be made with the use
of somatostatin in treatment of DKA.
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6.8. Monitoring
Successful management and early intervention for complications require close monitoring.
Timeline in DKA management are listed in Figure-3 [165]. The clinicians should be made a flow
chart to obtain all relevant incidents regarding the patient’s condition and clinical outcome [192].
Figure 3. Timeline in DKA management. GCS:Glascow Coma Scale, CBC:Complete Blood Counting, ECG:Electrocardio‐
gram, HR:Heart Rate, BP:Blood Pressure, BUN:Blood Urea Nitrogen, Cr: Creatinine, WBC:White Blood Cell, CRP:C-reac‐
tive protein, CE:Cerebral edema (adapted from reference 165)
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Recommendations  for  laboratory  monitoring  include;  hourly  vital  signs  and  neurologic
checks;  hourly  blood glucose  levels  for  the  first  4-6  hours  and then to  continue with  2
hour  intervals  in  the  following  period;  venous  blood  gases  every  2  hours  for  6  hours,
then every 4 hours,  Na,  K and ionized calcium every 2 hours for 6  hours then every 4
hours;  magnesium  and  phosphorus  every  4  hours;  blood  urea  nitrogen  and  creatinine
levels  (every  4  hours)  should  also  be  monitored  until  stable;  basic  metabolic  profile  at
admission  and  then  every  morning.  Fluid  intake  and  urinary  output  should  be  moni‐
tored [193-195].  These are the minimum requirements and should be revised for special
situations.  For example,  patients  with initially low potassium, more frequent (hourly)  K
measurements should be made with ECG monitoring [194,195] or if  patient’s  neurologi‐
cal  status  is  unstable  and has  a  high  risk  of  cerebral  edema,  more  frequent  neurologic
and vital sign checks (20-30 minutes) should be made [192].
Serum bicarbonate and anion gap are good markers of therapeutic response. Close monitor‐
ing of arterial blood gases and serum or urine ketones should not be used as predictor of
clinical improvement. Despite of successfull treatment by arresting ketogenesis, ketone lev‐
els may be considered unchanged or high, as beta-hydroxybutyrate converts to acetoacetate
and conventional (nitroprusside) testing detects only acetoacetate and acetone [135]. For
avoid this problem laboratory measurement or the use of a bedside fingerstick sample moni‐
tor for beta-hydroxybutyrate can be made. It is reasonable to reduce laboratory monitoring
frequency when acidosis resolves, the anion gap falls to near normal limits while response
to glycemic therapy becomes noticeable [135]. In the presence of persistent acidosis, despite
of successfull treatment; sepsis, concomitant illness or inadequate insulin dosing should be
kept in mind and further evaluation and intervention should be made [135,193].
7. Complications of diabetic ketoacidosis or it’s treatment
Most of the diabetes-related morbidity and mortality in T1DM can be attributed to compli‐
cations of DKA.
7.1. Hypoglycemia
Decrease in the plasma glucose concentration rate should be kept in the range of 50–75
mg/dl/hour. As ketoacidosis is corrected, a rapid decline in plasma glucose levels can be oc‐
cur and this may cause the blood glucose drop to hypoglycemia levels. Hypoglycemia leads
to the release of counter-regulatory hormones and this results with rebound ketosis which
can lengthen the duration of treatment. In addition to this, severe hypoglycemia can cause
cardiac arrhythmias, seizure or loss of consciousness, brain injury including coma or death.
The insulin infusion rate should be checked every hour until a steady glucose decline is ach‐
ieved and once the plasma glucose falls to <200-250 mg/dL (11.1-13.88 mmol/L), dextrose
should be added to replacement fluids to allow continued insulin administration and avoid
hypoglycemia [93].
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7.2. Rhabdomyolysis and renal failure
Acute renal failure (ARF) is an uncommon complication of DKA and rarely requires renal
replacement therapy and it may be severe and potentially life threatening [196,197]. The eti‐
ology of ARF associated with DKA is multifactorial. The most commonly cited causes are
hypovolemia, hypotension and rhabdomyolysis [196]. Prolonged profound ketoacidosis and
insulin infusions can lead to severe hypophosphatemia, mainly as a result of intracelluar
phosphate shifting [198-201]. Hypophosphatemia can be resulted with rhabdomyolysis.
Other risk factors for rhabdomyolysis are severe hyperglycemia and high osmolality. But
the pathogenic mechanism leading to rhabdomyolysis in DKA remains unclear. There are
few reported cases in literature which had rhabdomyolysis in DKA. There may be no symp‐
toms or the condition can present with a mild increase of creatine kinase or rarely significant
acute renal failure necessitating hemodialysis [202-205].
7.3. Peripheral venous thrombosis
In  DKA  treatment,  patients  may  require  central  vascular  access  for  intensive  fluid  re‐
placement.  However,  this  route  of  vascular  access  causes  many complications [206]  like
venous thromboembolism (VTE) [207]. Children with thrombophilia, malignancy, congen‐
ital  cardiac  disease,  acute  infection,  trauma and surgery  have  a  high risk  for  complica‐
tions of central  venous catheter (CVC) related VTE [206].  In the medical  literature there
have  been  few  reported  cases  CVC  related  VTE  in  DKA  children  without  known  risk
factors.  [208-210].  Thus,  DKA and its  treatment may promote a prothrombotic state and
activation  of  vascular  endothelium,  predisposing  to  thrombosis.  Whilst,  DKA  has  not
been identified as an isolated risk factor for CVC-related VTE in adults [211]. Where es‐
sential  for,  intensive  fluid replacement  in  DKA, these  lines  should be  removed as  soon
as  possible,  particularly  as  CVC-related  VTE  appears  to  occur  within  the  first  24-48
hours after insertion [210].
7.4. Pancreatitis
Acute pancreatitis is a well known complication of DKA in adults [212] but is unusual in
childhood.  In  children  with  DKA,  abdominal  pain  and vomiting  are  common.  In  addi‐
tion  to  this,  patients  with  DKA also  have  elevated  serum pancreatic  enzyme (amylase/
lipase)  concentrations without clinical  signs or symptoms and without radiographic evi‐
dence of pancreatitis [213,214]. Although hypertriglyceridemia is a known cause of acute
pancreatitis and elevated triglyceride concentrations are frequent during DKA, an associ‐
ation between elevated triglyceride concentrations in DKA and pancreatic enzyme eleva‐
tion  or  pancreatitis  have  not  be  showned  in  the  previous  studies  [213,215].  The
mechanism responsible  for  pancreatic  enzyme elevation in  DKA has  thus remained un‐
clear.  Physicians  should be  aware  of  this  phenomenon so  that  patients  with  DKA who
have  abdominal  pain  and  elevated  pancreatic  enzymes  are  not  erroneously  diagnosed
with acute pancreatitis  unless  in the presence of  persistent  abdominal  pain,  which does
not resolve with a successful treatment.
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7.5. Mucormycosis
Mucormycosis is an acute, rapidly progressing, and often fatal facultative fungal infection
occurs in patients with diabetes who have poor glycemic control and DKA, which have been
well established as predisposing factors for fungal growth. Mucormycosis can be classfied;
cutaneous, rhino-cerebral, pulmonary, gastrointestinal, central nervous system and dissemi‐
nated [216]. The rhino-cerebral forms develops in patients with diabetes, particularly with
the complication such as DKA. The most common symptoms are; facial pain, headache, fe‐
ver, and mental obtundation [217]. In the Figure 4 there is a patient of us, firstly diagnosed
T1DM with DKA infected by mucormycozis [218].
Figure 4. A 15 years old male patient firstly diagnosed T1DM with DKA infected by rhino-orbita-cerebral mucormyco‐
zis (Picture from the reference [218])
7.6. Pulmonary oedema
Pulmonary oedema is a rare, iatrogenic complication of DKA. Usually occurs within a few
hours of initiation of treatment related with rapid infusion of crystalloids over a short peri‐
od of time. Elderly patients and those with impaired cardiac/renal function are at high risk
and monitoring of central venous pressure should be considered [219].
7.7. Pneumomediastinum
Spontaneous pneumomediastinum is a rare pulmonary complication of DKA [220]. Kuss‐
maul breathing and repeated vomiting increases the intra-alveolar pressure; that leads to
alveolar rupture; then, the air penetrates peribronchial and perivascular spaces and reach
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the mediastinum. Extension into neck and subcutaneous tissue could be seen.  The most
common  sypmtoms  include  chest  pain  and  dyspnoea.  Treatment  is  mostly  supportive;
management  of  nausea/vomiting  along  with  correction  of  acidosis  to  break  Kussmaul
breathing  is  should  be  considered.  Patients  should  be  carefully  monitored  in  intensive
care settings [221-223].
7.8. Cerebral edema
Symptomatic  cerebral  edema (CE) is  rare in adults  treated for DKA, although asympto‐
matic  CE may be occur [224]  and may be present  before treatment [225].  In contrast  to
this, CE occurs in ~0.3–1.0% of DKA episodes in children [224,226) and is associated with
a  mortality  rate  of  20–40% [226]  and accounts  for  57–87% of  all  DKA deaths  [224,226].
Because of possible delay in diagnosis and more susceptibility to metabolic and vascular
changes, children <5 years of age have higher risk for the development of CE. The recog‐
nized  risk  factors  for  development  of  CE  are  acidosis,  hypocapnia  and  elevated  serum
urea nitrogen (indicator of  severity of  ketoacidosis  and dehydration)  [227].  The etiology
of CE is unknown; many mechanisms have been proposed including cerebral hypoperfu‐
sion with subsequent re-perfusion [228,229],  the generation of various inflammatory me‐
diators  [230],  increased  cerebral  blood  flow,  disruption  of  cell  membrane  ion  transport
and a rapid shift in extracellular and intracellular fluids resulting in changes in osmolali‐
ty.  Thus the etiology of  DKA-related CE is  multifactorial  and results  of  an interplay of
complex pathophysiological processes involving the brain [231-235]. The time of onset is
not the same in all affected individuals; two-thirds of patients develops signs and symp‐
toms in the first 6-7 hours and the rest from 10-24 hours after start of the treatment with
the early-onset individuals tending to be younger [182,236,237].
Muir et al. suggested a model for early detection. The system allowed 92% sensitivity and
96% specificity for the recognition of CE early enough for intervention. One diagnostic crite‐
rion, two major criteria or one major plus two minor criteria is suitable to establish CE [236].
Diagnostic criteria, major criteria and minor criteria are shown in Table 6.
Diagnostic criteria Major criteria Minor criteria
1. Abnormal motor or verbal
response to pain
2.Decorticate or decerebrate posture
3.Cranial nerve palsy (especially III, IV,
VI)
4.Abnormal neurogenic respiratory
pattern
(eg: grunting, tachypnea, Cheyne-
Stokes, apneustic)
1.Altered mentation and fluctuating
level of consciousness
2.Sustained heart rate deceleration
(decline more than 20 per minute)
not attributable to improved
intravascular volume or sleep state
3. Age inappropriate incontinence
1.Vomiting following initial
treatment and its cessation, if present
at admission
2. Headache (recurrent and more
severe than on admission)
3.Lethargy or not easily aroused from
sleep
4. Diastolic blood pressure greater
than 90 mmHg
5. Age <5 years
Table 6. Diagnostic criteria, major criteria and minor criteria for Cerebral Edema
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To prevent  the  development  CE the  following should  be  made;  avoiding  excessive  hy‐
dration  and  rapid  reduction  of  plasma  osmolarity,  a  gradual  decline  in  serum  glucose
and maintenance of serum glucose between 250–300 mg/dl until the patient’s mental sta‐
tus is improved [238].
First of all the rate of fluid administration should be decreased and head of the bed lifted up
[236]. Administration of IV mannitol in a dosage of 1.0 g/kg over 20 minutes when repeated
as necessary in 1-2 hours shows an improvement in clinical outcome [224,227,228,239]. Pa‐
tients who do not respond adequately to mannitol of a dose of 1 g/kg, 5-10 mL/kg 3% saline
infusion is an alternative treatment [240].
7.9. Intracerebral complications other than CE
Neurologic collapse during DKA can cause other intracerebral complications, with or with‐
out associated edema, but defined not idiopathic CE [227]. These include; subarachnoid
hemorrhage, basilar artery thrombosis [224], cerebral venous thrombosis [241,242], menin‐
goencephalitis [243] and disseminated intravascular coagulation [244,245].
8. Preventıon
DKA can be prevented by access to a 24-hours telephone helpline for emergency advice and
treatment, sufficient patient education and easier access to medical care. Especially patients
should be educated about a clinical condition which increases the risk of developing DKA
and the changes in the treatment at this situations.
These are includes the following;
1. Patients should be educated about what are the precipitating factors of DKA.
2. Early contact with a 24-hours telephone helpline or the health care provider should be
obtained in an acute illness.
3. The importance of insulin during an acute illness should be emphasized.
4. Patients should be advised never to discontinue insulin before contact with health care
provider.
5. Patients should be informed about blood glucose goals, the use of additional dose short
or rapid acting insulin and the medications available to suppress a fever and treat an
infection.
6. In the case of nause and vomiting an easily digestible liquid diet containing carbohy‐
drates and salt should be initiated.
7. Family members should be educated about sick day management and record keeping
including assessing and documenting temperature, blood glucose, and urine/blood ke‐
tone testing, insulin administration, oral intake and weight [93].
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Home measurement of blood glucose-ketone levels may allow early recognition of hyper‐
glycemia and ketosis. Adjusment of insulin therapy based on these findings may prevent
hospitalization for DKA [246].
9. Conclusıon
DKA is a life-threatening condition which is the most common cause of death in children
and adolescents with T1DM and a mortality rate <1% in adult subjects. DKA is a preventa‐
ble complication of T1DM. Education about the precipitating factors of DKA and rapid ac‐
cess to health care providers contributes to better outcomes and fewer recurrences. DKA can
be controlled in a period of 12-36 hours with an appropriate treatment. Thus, complications
can be prevented and reduction in mortality rates can be achieved.
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